Table 1 Clinicopathological characteristics of patients
| Â | Total |
|---|---|
No. of patients | 394 |
Age (years) | Â |
 Mean ± SD | 57.0 ± 12.8 |
 Range | 28-94 |
Tumor size (cm) | Â |
 ≤2.0 | 197 (50.0%) |
 2.1-5.0 | 183 (46.5%) |
 >5.0 | 12 (3.1%) |
 Unknown | 2 (0.4%) |
No. of positive lymph nodes | Â |
 0 | 207 (52.5%) |
 1-3 | 108 (27.4%) |
 4-9 | 23 (5.9%) |
 ≥10 | 15 (3.8%) |
 Unknown | 41 (10.4%) |
Tumor grade | Â |
 1 | 111 (28.2%) |
 2 | 113 (28.7%) |
 3 | 146 (37.1%) |
 Unknown | 24 (6.0%) |
ERα |  |
 Negative | 31(7.9%) |
 Positive | 363 (92.1%) |
PgR | Â |
 Negative | 86 (21.8%) |
 Positive | 306 (77.7%) |
 Unknown | 2 (0.5%) |
HER2 status | Â |
 Negative | 278 (70.6%) |
 Positive | 41 (10.4%) |
 Unknown | 75 (19.0%) |
Adjuvant therapy | Â |
 None | 30 (7.6%) |
 Endocrine therapy | 177 (44.9%) |
 Chemotherapy | 29 (7.4%) |
 Combined | 155 (39.3%) |
 Unknown | 3 (0.8%) |